Background
==========

The new antiepileptic drug (AED) oxcarbazepine (OXC) is a 10-keto analog of carbamazepine (CBZ). The clinical effectiveness of OXC is similar to that of CBZ, but with fewer adverse drug reactions (ADRs), which is attributed to their different metabolic pathways \[[@B1]\]. A common side effect associated with AED use is rash, and has been the leading cause of withdrawal from some AED trials \[[@B2]-[@B4]\]. Recently it was reported that the incidence of OXC-related skin rashes is 3-8% in Norwegian \[[@B5],[@B6]\] patients.

Cutaneous adverse drug reactions (cADRs) induced by AEDs range from mild maculopapular eruption (MPE) and hypersensitivity syndrome, to the more severe Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Among these cADRs, MPE is the most common \[[@B7]\], and is generally considered an initial form of the other, more severe, cADRs.

The pathogenesis of AED-induced cADRs is complex---several studies have indicated that T-cell-mediated allergic reactions might be associated with them \[[@B8]\], but genetic susceptibility and the exact pathogenesis are not fully understood and require further investigation. Recent studies have reported that the HLA-B\*1502 allele is strongly associated with a dramatically increased risk of CBZ-induced SJS/TEN, but not MPE, among Han Chinese living in Taiwan and Hong Kong \[[@B9],[@B10]\], that is, in southern China.

Owing to the structural similarity between OXC and CBZ, several studies of genetic susceptibility to OXC have been performed and an association between HLA-B\*1502 and OXC-cADRs has been reported. These included studies that suggested that HLA-B\*1502 may be associated with OXC-induced SJS/TEN \[[@B11],[@B12]\]. Other studies such as Zhou D \[[@B13]\]reported that the HLA-B\*1502 allele may contribute to genetic susceptibility to OXC-induced MPE in the Chinese Han population. However, there are also studies which found no significant association between HLA-B\* 1502 and OXC-MPE in southern Han Chinese people \[[@B14]\]. Because of the inconsistencies among these results and the fact that there has been no study conducted to test the association between HLA-B\*1502 and OXC-MPE in the northern Han Chinese population specifically, we carried out the following retrospective study. Herein we report our investigations into the association between OXC-induced MPE and HLA-B alleles. We also analyzed the clinical risk factors for OXC-induced MPE in a northern Han Chinese population.

Methods
=======

Patients
--------

All of the enrolled subjects (patients and normal controls) were of Northern Han Chinese ethnicity. Patients were from towns in Jilin Province (Hua Dian, Pan Shi, Tao Nan, Jiao He, and Shu Lan). The Ethics Committee of Jilin University at Changchun, and the Ethics Committee of Second Affiliated Hospital of Guangzhou Medical University at Guangzhou approved this study. All of the study participants provided written informed consent.

During the years 2010--2012, 14 cases that fulfilled the diagnostic criteria for OXC-induced MPE (OXC-MPE) were identified at the Department of Neurology, First Hospital of Jilin University, Changchun, China. MPE was defined as erythematous exanthema without blistering or postulation. The attribution of MPE to OXC treatment was determined jointly by the treating epileptologist and dermatologist.

We enrolled 28 subjects who had been administered OXC for more than 3 months but had not developed any cADRs (OXC-tolerant). In addition, for the normal control group we used the HLA-B allele frequencies reported in the Allele Frequency Net Database. Two control groups were used in this study, including 618 persons in Beijing, Shijiazhuang, Tianjin and 105 persons in the northern Han population (<http://www.allelefrequencies.net>).

Data collected from the patients' records included: age, gender, initial and final dose of OXC, and latency to MPE (starting from the initial dose).

Method
------

DNA was extracted from peripheral blood using a QIARamp blood mini kit (Qiagen, Hilden, Germany). The presence of HLA-B\*1502 was examined via polymerase chain reaction with sequence-specific primers as in previous reports \[[@B14],[@B15]\]. Sequencing for four-digit genotype determination was performed for all of the OXC-MPE and OXC-tolerant patients on an ABI 3730 sequencer (Applied Biosystems, Foster City, CA, USA). The forward and reverse primer sequences were Bin1-TAF (5\'-TGGCGGGGGCGCAGGACCTGA-3\') or Bin1-CGF (5\'-TCGGGGGCGCAGGACCCGG-3\') and Bin3-R (5\'-CGGAGGCCATCCCCGGCGACCTAT-3\'). Four-digit alleles of HLA-B in all patients were determined by sequence alignment using the immunogenetics/human leukocyte antigen (IMGT/HLA) database (<http://www.ebi.ac.uk/imgt/hla>) and the software vector NTI 6.0 (InforMax, Gaithersburg, MD, USA).

Statistical analysis
--------------------

Student's *t*-test for independent samples was used to determine the significance of differences in mean age and dosage between the OXC-MPE and the OXC-tolerant groups. The chi-squared test and Fisher's exact test were carried out to analyze the association between OXC-MPE and HLA-B alleles. To reduce bias in estimating the odds ratio (OR), whenever a zero-count field was encountered, 0.5 was added to all the fields in the 2×2 table \[[@B16]\]. The *P*-value from continuity correction (n ≥ 40 but 1 ≤ T ≤5) or Fisher's exact test (n \< 40 or T \< 1), as well as estimated ORs and 95% exact confidence intervals (CIs), were established. *P*-values less than 0.05 (two-sided) were considered statistically significant. All analyses were performed using SPSS version 16.0 software (SPSS, Chicago, IL, USA).

Results
=======

Fourteen patients who had been diagnosed with OXC-induced MPE (9 females, 5 males; mean age 34.43 ± 12.10 y) and 28 patients who received OXC for at least 3 months without any evidence of adverse drug reactions (17 females, 11 males; mean age 34.04 ± 12.85 y) were enrolled as cases (OXC-MPE) and tolerant controls (OXC-tolerant), respectively. For the normal control group, we used the Allele Frequency Net Database (<http://www.allelefrequencies.net>, see Table [1](#T1){ref-type="table"}).

###### 

Clinical characteristics and genotypes in the 14 patients with OXC-induced MPE and in the 28 OXC-tolerant controls

  **OXC-induced MPE**                                                                                                                                       
  --------------------- ------------ --------------- ----------------------- --------------------- ----------------- --------------------- ---------------- -----------------------
  1                     M            MPE             300                     600                   12                N                     Negative         HLA-B\*4001/4001
  2                     F            MPE             300                     600                   11                N                     Negative         HLA-B\*1302/4601
  3                     F            MPE             300                     450                   16                N                     Negative         HLA-B\*1302/1302
  4                     M            MPE             300                     600                   9                 N                     Negative         HLA-B\*1501/5101
  5                     F            MPE             300                     450                   15                N                     Negative         HLA-B\*1501/1527
  6                     M            MPE             300                     600                   12                N                     Negative         HLA-B\*1501/4403
  7                     F            MPE             300                     900                   16                N                     Negative         HLA-B\*1501/1542
  8                     M            MPE             300                     600                   11                N                     Negative         HLA-B\*4001/1558
  9                     F            MPE             300                     900                   17                N                     Negative         HLA-B\*3802/4403
  10                    F            MPE             300                     450                   8                 N                     Negative         HLA-B\*5201/5301
  11                    F            MPE             300                     600                   10                N                     Negative         HLA-B\*5502/5601
  12                    F            MPE             300                     750                   14                N                     positive         HLA-B\*3802/1502
  13                    M            MPE             300                     750                   12                N                     Negative         HLA-B\*1301/1301
  14                    F            MPE             300                     600                   9                 N                     Negative         HLA-B\*4402/3802
  **OXC-tolerant**                                                                                                                                          
  **ID No.**            **Gender**   **Phenotype**   **Initial-dose (mg)**   **Final-dose (mg)**   **Latency (d)**   **Concurrent drug**   **HLA-B 1502**   **Four-digit allele**
  15                    F            Tolerant        300                     900                   N                 N                     Negative         HLA-B\*4801/3531
  16                    F            Tolerant        300                     600                   N                 N                     Negative         HLA-B\*4403/4804
  17                    M            Tolerant        300                     600                   N                 N                     Negative         HLA-B\*4001/5501
  18                    M            Tolerant        300                     900                   N                 N                     Negative         HLA-B\*3802/4403
  19                    F            Tolerant        300                     900                   N                 N                     Negative         HLA-B\*4403/4403
  20                    M            Tolerant        300                     600                   N                 N                     Negative         HLA-B\*3802/1302
  21                    F            Tolerant        300                     600                   N                 N                     Negative         HLA-B\*4801/3531
  22                    M            Tolerant        300                     450                   N                 N                     Negative         HLA-B\*4601/1511
  23                    M            Tolerant        300                     600                   N                 N                     Negative         HLA-B\*1501/4001
  24                    F            Tolerant        300                     450                   N                 N                     Negative         HLA-B\*1511/4801
  25                    F            Tolerant        300                     600                   N                 N                     Negative         HLA-B\*4403/5604
  26                    F            Tolerant        300                     900                   N                 N                     Negative         HLA-B\*1302/5801
  27                    M            Tolerant        300                     900                   N                 N                     Negative         HLA-B\*1302/0705
  28                    F            Tolerant        300                     600                   N                 N                     Negative         HLA-B\*3710/4701
  29                    F            Tolerant        300                     600                   N                 N                     Negative         HLA-B\*1302/1315
  30                    F            Tolerant        300                     600                   N                 N                     Negative         HLA-B\*1302/3901
  31                    F            Tolerant        300                     900                   N                 N                     Negative         HLA-B\*5102/3508
  32                    M            Tolerant        300                     900                   N                 N                     Negative         HLA-B\*5502/3801
  33                    F            Tolerant        300                     450                   N                 N                     Negative         HLA-B\*1501/1513
  34                    F            Tolerant        300                     600                   N                 N                     Negative         HLA-B\*1301/1301
  35                    M            Tolerant        300                     600                   N                 N                     Negative         HLA-B\*2705/5101
  36                    M            Tolerant        300                     450                   N                 N                     Negative         HLA-B\*4801/4801
  37                    F            Tolerant        300                     600                   N                 N                     positive         HLA-B\*1502/4001
  38                    F            Tolerant        300                     750                   N                 N                     positive         HLA-B\*5801/1502
  39                    F            Tolerant        300                     900                   N                 N                     Negative         HLA-B\*4001/4006
  40                    M            Tolerant        300                     600                   N                 N                     positive         HLA-B\*1502/5801
  41                    M            Tolerant        300                     450                   N                 N                     positive         HLA-B\*4601/1502
  42                    F            Tolerant        300                     900                   N                 N                     positive         HLA-B\*4601/1502

*OXC*, oxcarbazepine; *MPE*, maculopapular eruption; F, female; *M*, male.

The genotyping showed that HLA-B\*1502 was present in only one of the 14 (7.1%) OXC-MPE patients, whereas 5 of the 28 (17.9%) OXC-tolerant controls carried this allele. The differences in the presence of HLA-B\*1502 between the two groups was not statistically significant (OR = 0.35, 95% CI = 0.04--3.36, *P* = 0.64).

Four-digit allele sequencing showed that there was no statistically significant difference in the frequency of the HLA-B\*1502 allele between the OXC-MPE and the OXC-tolerant control groups (3.6% versus 8.9%, OR = 0.38, 95% CI = 0.04--3.40, *P* = 0.65), as well as between the OXC-MPE group and the normal control group (3.6% versus 2.4%, OR = 1.54, 95% CI = 0.20--11.73, *P* = 0.49). Moreover, there were no significant differences between the OXC-MPE and the OXC-tolerant groups with regard to the frequencies of other HLA-B alleles. However, when the general northern Han population was used as a normal control, the frequency of the HLA-B\*3802 allele was found to be significantly higher in the OXC-MPE group (10.7% versus 1.9%, OR = 6.329, 95% CI = 1.783-22.460, *P* = 0.018; Table [2](#T2){ref-type="table"}).

###### 

Frequencies of HLA-B alleles and their associations with OXC-induced MPE

         **Frequency**   **MPE cases compared with OXC-tolerant controls**   **MPE cases compared with normal population controls**                                                        
  ------ --------------- --------------------------------------------------- -------------------------------------------------------- --------------------- ------ ----------------------- -----------
  0705   0/28 (0)        1/56 (1.8)                                          4/1236 ^c^ (0.4)                                         0.65 (0.03--16.45)    1.00   4.81 (0.25--91.38)      1.00
  1301   2/28 (7.1)      2/56 (3.6)                                          44/1236 ^c^ (3.6)                                        2.08 (0.28--15.58)    0.86   2.08 (0.48--9.06)       0.62
  1302   3/28 (10.7)     5/56 (8.9)                                          69/1236 ^c^ (5.5)                                        1.22 (0.27--5.54)     1.00   2.03 (0.60--6.89)       0.46
  1315   0/28 (0)        1/56 (1.8)                                          --                                                       0.65 (0.03--16.45)    1.00   --                      --
  1501   4/28 (14.3)     2/56 (3.6)                                          86/1236 ^c^ (7.0)                                        4.50 (0.77--26.27)    0.18   2.23 (0.76--6.57)       0.26
  1502   1/28 (3.6)      5/56 (8.9)                                          29/1236 ^c^ (2.4)                                        0.38 (0.04--3.40)     0.65   1.54 (0.20--11.73)      0.49
  1511   0/28 (0)        2/56 (3.6)                                          21/1236 ^c^ ( 1.7)                                       0.38 (0.02--8.24)     0.55   0.99 (0.06--16.78)      1.00
  1513   0/28 (0)        1/56 (1.8)                                          1/1236 ^c^ (0.1)                                         0.65 (0.03--16.45)    1.00   14.45 (0.58--362.44)    1.00
  1527   1/28 (3.6)      0/56 (0)                                            2/1236 ^c^ (0.2)                                         6.16 (0.24--156.27)   0.33   22.85 (2.01--259.72)    0.07
  1542   1/28 (3.6)      0/56 (0)                                            0/210 ^d^ (0)                                            6.16 (0.24--156.27)   0.33   22.96 (0.91--577.76)    0.12
  1558   1/28 (3.6)      0/56 (0)                                            2/1236 ^c^ (0.2)                                         6.16 (0.24--156.27)   0.33   22.85 (2.01--259.72)    0.07
  2705   0/28 (0)        1/56 (1.8)                                          6/1236 ^c^ (0.5)                                         0.65 (0.03--16.45)    1.00   3.32 (0.18--60.38)      1.00
  3508   0/28 (0)        1/56 (1.8)                                          1/1236 ^c^ (0.1)                                         0.65 (0.03--16.45)    1.00   14.45 (0.58--362.44)    1.00
  3531   0/28 (0)        2/56 (3.6)                                          0/210 ^d^ (0)                                            0.38 (0.02--8.24)     0.55   --                      --
  3710   0/28 (0)        1/56 (1.8)                                          --                                                       0.65 (0.03--16.45)    1.00   --                      --
  3801   0/28 (0)        1/56 (1.8)                                          8/1236 ^c^ (0.7)                                         0.65 (0.03--16.45)    1.00   2.54 (0.14--45.00)      1.00
  3802   3/28 (10.7)     2/56 (3.6)                                          23/1236 ^c^ (1.9)                                        3.24 (0.51--20.63)    0.42   6.329 (1.783--22.460)   0.018 ^e^
  3901   0/28 (0)        1/56 (1.8)                                          23/1236 ^c^ (1.9)                                        0.65 (0.03--16.45)    1.00   0.91 (0.05--15.29)      1.00
  4001   3/28 (10.7)     4/56 (7.1)                                          100/1236 ^c^ (8.1)                                       1.56 (0.32--7.51)     0.89   1.36 (0.41--4.59)       0.88
  4006   0/28 (0)        1/56 (1.8)                                          39/1236 ^c^ (3.2)                                        0.65 (0.03--16.45)    1.00   0.53 (0.03--8.87)       1.00
  4402   1/28 (3.6)      0/56 (0)                                            11/1236 ^c^ (0.9)                                        6.16 (0.24--156.27)   0.33   4.13 (0.51--33.09)      0.24
  4403   2/28 (7.1)      5/56 (8.9)                                          32/1236 ^c^ (2.6)                                        0.79 (0.14--4.32)     1.00   2.89 (0.66--12.72)      0.17
  4601   1/28 (3.6)      3/56 (5.4)                                          118/1236 ^c^ (9.6)                                       0.65 (0.07--6.59)     1.00   0.35 (0.05--2.61)       0.46
  4701   0/28 (0)        1/56 (1.8)                                          0/210 ^d^ (0)                                            0.65 (0.03--16.45)    1.00   --                      --
  4801   0/28 (0)        5/56 (8.9)                                          24/1236 ^c^ (2)                                          0.16 (0.01--3.08)     0.25   0.87 (0.05--14.63)      1.00
  4804   0/28 (0)        1/56 (1.8)                                          0/210 ^d^ (0)                                            0.65 (0.03--16.45)    1.00   --                      --
  5101   1/28 (3.6)      1/56 (1.8)                                          66/1236 ^c^ (5.4)                                        2.04 (0.12--33.83)    1.00   0.66 (0.09--4.91)       1.00
  5102   0/28 (0)        1/56 (1.8)                                          6/1236 ^c^ (0.5)                                         0.65 (0.03--16.45)    1.00   3.32 (0.18--60.38)      1.00
  5201   1/28 (3.6)      0/56 (0)                                            21/1236 ^c^ (1.9)                                        6.16 (0.24--156.27)   0.33   2.14 (0.28--16.51)      0.39
  5301   1/28 (3.6)      0/56 (0)                                            0/210 ^d^ (0)                                            6.16 (0.24--156.27)   0.33   22.96 (0.91--577.76)    0.12
  5501   0/28 (0)        1/56 (1.8)                                          7/1236 ^c^ (0.6)                                         0.65 (0.03--16.45)    1.00   2.88 (0.16--51.58)      1.00
  5502   1/28 (3.6)      1/56 (1.8)                                          35/1236 ^c^ (2.9)                                        2.04 (0.12--33.83)    1.00   1.27 (0.17--9.62)       0.56
  5601   1/28 (3.6)      0/56 (0)                                            2/1236 ^c^ (0.2)                                         6.16 (0.24--156.27)   0.33   22.85 (2.01--259.72)    0.07
  5604   0/28 (0)        1/56 (2.5)                                          1/1236 ^c^ (0.1)                                         0.65 (0.03--16.45)    1.00   14.45 (0.58--362.44)    1.00
  5801   0/28 (0)        3/56 (5.3)                                          74/1236 ^c^ (6)                                          0.27 (0.01--5.38)     0.55   0.27 (0.02--4.53 )      0.35

^a^ 2n = 28.

^b^ 2n = 56.

^c^ 2n = 1236, from a China Beijing Shijiazhuang Tianjin Han population of 618 persons (<http://www.allelefrequencies.net>).

^d^ 2n = 210, from a China North Han population of 105 persons (<http://www.allelefrequencies.net>). Note: The frequency of these alleles has not been reported by the former.

OXC, oxcarbazepine; MPE, maculopapular eruption; OR, odds ratio; CI: confidence interval.

^e^*P* \< 0.05 (two-sided) was statistically significant.

--, no data available.

There was no significant difference between the patients with or without OXC-MEP in terms of age (34.43 ± 12.10 versus 34.04 ± 12.85, *P* = 0.93), gender (male/female: 5/9 versus 11/17, OR = 0.86, 95% CI = 0.23-3.25, *P* = 0.82), or final dose (632.14 ± 146.24 mg/d versus 675.00 ± 170.78 mg/d, *P* = 0.43; Table [1](#T1){ref-type="table"}).

Discussion
==========

In the present study we found no association between OXC-induced MPE and HLA-B\*1502 in our northern Han Chinese patients. Our result is consistent with previous studies of southern Han Chinese \[[@B14]\], but different from another study showing a significant association between OXC-induced MPE and HLA-B\*1502 in central Han Chinese \[[@B7]\]. These discrepancies could mainly be due to differences in the frequency of HLA-B\*1502 in different populations. Of note, in each of these studies the sample size was small, which limited the power of the statistical analyses.

Among Han Chinese living in Taiwan and Hong Kong (southern China), HLA-B\*1502 was strongly associated with a dramatically increased risk of CBZ-induced SJS/TEN, but was not associated with MPE \[[@B10]\]. Recently, three OXC-induced SJS/TEN cases reported from Taiwan were positive for HLA-B\*1502 \[[@B17]\], and there was one case of OXC-induced SJS positive for HLA-B\*1502 in India \[[@B18]\]. This suggests a very strong association between OXC-induced SJS/TEN and the HLA-B\*1502 allele. In our study, we found that the HLA-B\*1502 allele was only present in 7.1% of OXC-induced MPE patients in this northern Han Chinese population.

This may be due to the inflammatory immune reactions of MPE different from SJS/TEN. CD4 ^+^ T cells are the major cell type found in the skin lesions of MPE \[[@B19]\], whereas CD8 ^+^ T-cell-mediated cytotoxic responses appear to be the major event in SJS/TEN \[[@B20]\].

OXC is a new AED which has shown clinical effectiveness similar to that of CBZ but with fewer adverse drug reactions; therefore OXC is now frequently used as a substitute for CBZ. Rash is a common side effect of AED therapy and is the leading cause of withdrawal from AED prescriptions. Some of these rashes can be ameliorated by early-stage therapy with additional management to prevent them from developing into more severe cutaneous reactions that could be fatal, while discontinuing OXC due to skin eruption prevents the long-term use of what would otherwise be an effective drug, and increases the suffering of patients. Hence, identifying the possible risk factors for cADRs will contribute to their prevention and the safe use of OXC.

We therefore compared the frequencies of HLA-B alleles other than HLA-B\*1502 between the OXC-MPE and the OXC-tolerant groups. We found an association between the HLA-B\*3802 allele and OXC-induced MPE in the northern Han Chinese population we studied; the frequency of the HLA-B\*3802 allele was significantly higher in the OXC-MPE group. However, it should be noted that the general northern Han population was used as a control group. When OXC-tolerant subjects were used as a control, there was no statistically significant difference in the frequency of the HLA-B\*3802 allele between the OXC-MPE and the OXC-tolerant control groups. This discrepancy may be because this is a small sample study, and therefore the statistical power to detect any significant difference between cases and controls was limited. Whether the HLA alleles identified in this exploratory study would be associated with the development of OXC-induced MPE in a larger sample needs to be investigated.

Hung et al. \[[@B9]\] found that MPE induced by CBZ was associated with single nucleotide polymorphisms (SNPs) in the HLA-E region and the nearby allele HLA-A\*3101, but hypersensitivity syndrome was associated with SNPs in the motilin gene located terminal to the major histocompatibility complex (MHC) class II genes \[[@B8]\]. Therefore, the association between OXC-induced skin rashes and other HLA alleles beyond HLA-B should be explored in future research.

Our analysis of potential risk factors for OXC-induced MPE in the present study showed that neither age, gender, nor final dose of OXC were associated with incidence of the skin rash, which is consistent with previous studies in Korea \[[@B21]\]. However, other related studies showed that several clinical variables affected skin reactions, including gender, hormones, the drug titration schedule, and co-medication \[[@B22]\]. Among these variables, a high starting dose and rapid dose escalation were identified as risk factors, especially for the AED lamotrigine, and particularly when administered concurrent with valproate \[[@B23]\]. In addition, it has been reported that a reaction to one AED may induce hypersensitivity to a previously tolerated AED, and a previous AED-related skin reaction appears to be a considerable risk factor for occurrence of another rash \[[@B24]\]. The differences between our study and those cited above may be because all of the patients in our study were given monotherapy, treated with the same initial dosage, and the small sample size.

Conclusion
==========

In conclusion, we found no significant association between OXC-induced MPE and the HLA-B\*1502 allele in the northern Han Chinese patients we studied. Instead, in this Han Chinese population HLA-B\*3802 was identified as a potential risk factor for OXC-MPE. Furthermore, no association was found between OXC-MPE and age, gender, or dosage. It should be noted that this is a small-sample study, which limited the statistical power to detect any significant difference. Therefore, our results need to be further confirmed by a future study with a larger sample size.
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